Works Cited

1. Centers for Disease Control and Prevention. About Opioid Use During Pregnancy. Available at https://www.cdc.gov/pregnancy/opioids/basics.html. Last accessed December 1, 2023.

2. Elmore AL, Omofuma OO, Sevoyan M, Richard C, Liu J. Prescription opioid use among women of reproductive age in the United States: NHANES, 2003–2018. Prev Med. 2021;153:106846.

3. U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA Updates Prescribing Information for All Opioid Pain Medicines to Provide Additional Guidance for Safe Use. Available at https://www.fda.gov/media/167058/download?attachment. Last accessed December 1, 2023.

4. Centers for Disease Control and Prevention. Prescription Painkiller Overdoses: A Growing Epidemic, Especially Among Women. Available at https://www.cdc.gov/vitalsigns/prescriptionpainkilleroverdoses. Last accessed October 16, 2020.

5. Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC clinical practice guideline for prescribing opioids for pain—United States, 2022. MMWR. 2022;71(3):1-95.

6. Osborne NR, Davis KD. Chapter eight: sex and gender differences in pain. Int Rev Neurobiol. 2022;164:277-307.

7. Sharma B, Bruner A, Barnett G, Fishman M. Opioid use disorders. Child Adolesc Psychiatr Clin N Am. 2016;25(3):473-487.

8. Medline Plus. Opiate and Opioid Withdrawal. Available at https://medlineplus.gov/ency/article/000949.htm. Last accessed December 1, 2023.

9. Substance Abuse and Mental Health Services Administration. Treatment Improvement Protocol (TIP) 63: Medications for Opioid Use Disorder. Available at https://store.samhsa.gov/sites/default/files/pep21-02-01-002.pdf. Last accessed December 1, 2023.

10. Substance Abuse and Mental Health Services Administration. Evidence-Based, Whole-Person Care for Pregnant People Who Have Opioid Use Disorder. Available at https://store.samhsa.gov/sites/default/files/pep23-02-01-002.pdf. Last accessed December 1, 2023.

11. Nilsson L, Forsell L. A Child is Born. 5th ed. New York, NY: Bantam Dell; 2020.

12. Lin-Fu JS. Neonatal Narcotic Addiction. Rockville, MD: U.S. Department of Health Education and Welfare; 1969.

13. Patrick SW, Barfield WD, Poindexter BB. Neonatal opioid withdrawal syndrome. Pediatrics. 2020;146(5):e2020029074.

14. Moss-King. The Positive Direction Model: Opioid Use and Pregnancy. Bloomington, IN: AuthorHouse; 2017.

15. Centers for Disease Control and Prevention. Treatment for Opioid Use Disorder Before, During, and After Pregnancy. Available at https://www.cdc.gov/pregnancy/opioids/treatment.html. Last accessed December 1, 2023.

16. Jones HE, Finnegan LP, Kaltenbach K. Methadone and buprenorphine for the management of opioid dependence in pregnancy. Drugs. 2012;72(6):747-757.

17. American College of Obstetricians and Gynecologists Committee on Obstetric Practice, American Society of Addiction Medicine. ACOG committee opinion no. 711: opioid use and opioid use disorder in pregnancy [reaffirmed 2021]. Obstet Gynecol. 2017;130(2):e81-e94.

18. Wadman E, Fernandes E, Muss C, et al. A novel syndrome associated with prenatal fentanyl exposure. Gen Med Open. 2023;9(1):100834.

19. Substance Abuse and Mental Health Services Administration. Buprenorphine. Available at https://www.samhsa.gov/medications-substance-use-disorders/medications-counseling-related-conditions/buprenorphine. Last accessed December 1, 2023.

20. Franck LS, Harris SK, Soetenga DJ, Amling JK, Curley MAQ. The withdrawal assessment tool—version 1 (WAT-1): an assessment instrument for monitoring opioid and benzodiazepine withdrawal symptoms in pediatric patients. Pediatric Critical Care Medicine. 2008;9(6):573-580.

21. Ram A, Tuten M, Chisolm MS. Cigarette smoking reduction in pregnant women with opioid use disorder. J Addict Med. 2016;10(1):53-59.

22. Blandthorn J, Forster DA, Love V. Neonatal and maternal outcomes following maternal use of buprenorphine or methadone during pregnancy: findings of retrospective audit. Women Birth. 2011;24(1):32-39.

23. Hudak ML, Tan RC, the Committee on Drugs, the Committee on Fetus and Newborn of the American Academy of Pediatrics. Neonatal drug withdrawal. Pediatrics. 2012;129(2):e540-e560.

24. McQueen K, Murphy-Oikonen J. Neonatal abstinence syndrome. N Engl J Med. 2016;375(25):2468-2479.

25. Welle-Strand GK, Skurtveit S, Jansson LM, Bakstad B, Bjarkø L, Ravndal E. Breastfeeding reduces the need for withdrawal treatment in opioid-exposed infants. Acta Paediatr. 2013;102(11):1060-1066.

26. Finnegan, LP, Kron, RE, Connaughton, JF, Emich, JP, A scoring system for evaluation and treatment of the neonatal abstinence syndrome: a new clinical and research tool. In: Moriselli PL, Garattini S, Sereni F (eds). Basic and Therapeutic Aspects of Perinatal Pharmacology. New York, NY: Raven Press; 1975: 139-155.

27. Weller AE, Crist RC, Reiner BC, Doyle GA, Berrettini WH. Neonatal opioid withdrawal syndrome (NOWS): a transgenerational echo of the opioid crisis. Cold Spring Harb Perspect Med. 2021;11(3):a039669.

28. Pallatino C, Chang JC, Krans EE. The intersection of intimate partner violence and substance use among women with opioid use disorder. Subst Abus. 2021;42(2):197-204.

29. Conradt E, Flannery T, Aschner JL, et al. Prenatal opioid exposure: neurodevelopmental consequences and future research priorities. Pediatrics. 2019;144(3):e20190128.

30. Substance Abuse and Mental Health Services Administration. Clinical Guidance for Treating Pregnant and Parenting Women with Opioid Use Disorder and Their Infants. HHS Publication No. (SMA) 18-5054. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2018.

31. Grim K, Harrison TE, Wilder RT. Management of neonatal abstinence syndrome from opioids. Clin Perinatol. 2013;40(3):509-524.

Evidence-Based Practice Recommendations Citations

1. World Health Organization. Guidelines for the Identification and Management of Substance Use and Substance Use Disorders in Pregnancy. Geneva: World Health Organization; 2014. Available at https://www.who.int/publications/i/item/9789241548731. Last accessed December 14, 2020.


Copyright © 2024 NetCE, PO Box 997571, Sacramento, CA 95899-7571
Mention of commercial products does not indicate endorsement.